The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

Biological Psychiatry

Volumn 46, Issue 9, 1999, Pages 1243-1252

  Friedman, Joseph I ^a   Adler, David N ^a   Davis, Kenneth L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cholinergic; Cognitive; Noradrenergic; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; DONEPEZIL; GUANFACINE; NEUROLEPTIC AGENT; NORADRENALIN; PHYSOSTIGMINE; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; BRAIN REGION; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; HUMAN; LOCUS CERULEUS; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ADRENERGIC ALPHA-AGONISTS; ALZHEIMER DISEASE; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; HUMANS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-2; SCHIZOPHRENIA;

EID: 0033232474     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00232-2     Document Type: Review

References (99)

1. Acheson A.L., Zigmond M.J. Short- and long-term changes in tyrosine hydroxylase activity in rat brain after subtotal destruction of central noradrenergic neurons. J Neurosci. 1:1981;493-504.
2. Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry. 135:1979;216-223.
3. Anlezark G.M., Crow T.J., Greenway A.P. Impaired learning an decreased cortical norepinephrine afterbilater locus coeruleus lesions. Science. 181:1973;682-684.
4. Aoki C., Go C.G., Venkatesan C., Kurose H. Peri-Karyal and synaptic localization of α-2A adrenergic receptorlike immunoreactivity. Brain Res. 650:1994;181-204.
5. Arnsten A.F., Cai J.X., Goldman Rakic P.S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects Evidence for alpha-2 receptor subtypes . J Neurosci. 8:1988;4287-4298.
6. Arnsten A.F., Goldman Rakic P.S. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science. 230:1985;1273-1276.
7. Arnsten A.F.T., Mathew R., Ubriani R., Taylor J.R., Li B.-M. α-1 Noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry. 45:1999;26-31.
8. Arnsten A.F.T., Steere J.C., Hunt R.D. The contribution of α-2 noradrenergic mechanisms to prefrontal cortical cognitive function. Arch Gen Psychiatry. 53:1996;448-455.
9. Bartus R., Uehara Y. Physostigmine and recent memory effects in young and aged non-human primates. Science. 206:1979;1085-1087.
10. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., et al. Neurochemical correlates of dementia severity in Alzheimer's disease Relative importance of the cholinergic deficits . J Neurochem. 64:1995;749-760.
11. Bierer L.M., Aisen P.S., Davidson M., Ryan T.M., Schmeidler J., Davis K.L. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 5:1994;243-246.
12. Bird E.D., Spokes E.G., Iversen L.L. Brain norepinephrine and dopamine in schizophrenia. Science. 204:1974;93-94.
13. Bird T.D., Stranahan S., Sumi S.M., Raskind M. Alzheimer's disease Choline acetyltransferase activity in brain tissue from clinical and pathological subgroups . Ann Neurol. 14:1983;284-293.
14. Bondareff W., Mountjoy C.Q., Roth M. Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet. 1:1981;783-784.
15. Bondareff W., Mountjoy C.Q., Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 32:1982;164-168.
16. Bondareff W., Mountjoy C.Q. Number of neurons in nucleus locus ceruleus in demented and non-demented patients Rapid estimation and correlated parameters . Neurobiol Aging. 7:1986;297-300.
17. Bridge T.P., Kleinman J.E., Karoum F., Wyatt R.J. Postmortem central catecholamines and ante mortem cognitive impairment in elderly schizophrenics and controls. Biol Psychiatry. 14:1985;57-61.
18. Buzsaki G., Kennedy B., Solt V.B., Ziegler M. Noradrenergic control of thalamic oscillation The role of alpha-2 receptors . Eur J Pharmacol. 3:1991;222-229.
19. Cahill L., Prins B., Weber M., McGaugh J.L. Beta-adrenergic activation and memory for emotional events. Nature. 371:1994;702-704.
20. Carli M., Robbins T.W., Evenden J.L., Everitt B.J. Effects of lesions to ascending noradrenergic neurons on performance of a 5-choice serial reaction task in rats. Implications for theories of dorsal noradrenergic bundle functions based on selective attention and arousal. Behav Brain Res. 9:1983;361-380.
21. Chrobak J.J., DeHaven D.L., Walsh T.J. Depletion of brain norepinephrine with DSP-4 does not alter acquisition or performance of a radial-arm maze task. Behav Neural Biol. 44:1985;144-150.
22. Cole B.J., Robbins T.W. Forebrain norepinephrine Role in controlled information processing in the rat . Neuropsychopharmacology. 7:1992;129-141.
23. Cross A.J., Crow T.J., Ferrier I.N., Johnson J.A., Bloom S.R., Corsellis J.A. Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem. 43:1984;1574-1581.
24. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J Clin Res Ed. 282:1981;93-94.
25. Crow T.J., Baker H.F., Cross A.J., Joseph M.H., Lofthouse R., Longden A., et al. Monoamine mechanisms in chronic schizophrenia Post-mortem neurochemical findings . Br J Psychiatry. 134:1979;249-256.
26. Crow T.J. Cortical synapses and reinforcement. Nature. 219:1968;736-737.
27. Crowe S.F., Shaw S. Salbutamol overcomes the effect of the noradrenergic neurotoxin DSP-4 on memory function in the day old chick. Behav Pharmacol. 8:1997;216-222.
28. Davies P., Katzman R., Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature. 288:1980;279-280.
29. Devauges V., Sara S.J. Activation of the noradrenergic system facilitates an attention shift in the rat. Behav Brain Research. 39:1990;19-29.
30. Elrod R., Peskind E.R., DiGiacomo L., Brodkin K.I., Veith R.C., Raskind M.A. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry. 154:1997;25-30.
31. Farley I.J., Price K.S., McCullouough E., Deck J.H.N., Hordynsky W., Hornykiewicz O. Norepinephrine in chronic paranoid schizophrenia Above-normal levels in limbic forebrain . Science. 200:1978;456-457.
32. Fields R.B., van Kammen D.P., Peters J.L., Rosen J., van Kammen W.B., Nugent A., et al. Clonidine improves memory function in schizophrenia independently from changes in psychosis Preliminary findings . Schizophr Res. 1:1988;417-423.
33. Flicker C., Dean R.L., Watkins D.L., Fisher S.K., Bartus R.T. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol Biochem Behav. 18:1983;973-981.
34. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:1975;189-198.
35. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N Engl J Med. 313:1985;7-11.
36. Fritschy J.M., Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons Compensatory response to neurotoxin-induced cell death in the adult rat brain . J Comp Neurol. 321:1992;421-441.
37. Goldman-Rakic P.S., Lidow M.S., Gallager D.W. Overlap of dopaminergic, adrenergic and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci. 10:1990;2125-2138.
38. Gottfries C.G., Adolfsson R., Aquilonius S.M., Carlsson A., Eckernas S.A., Nordberg A., et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging. 4:1983;261-271.
39. Greenblatt D.J., Scavone J.M., Harmatz J.S., Engelhardt N., Shader R.I. Cognitive effects of beta-adrenergic antagonists after single doses; pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam and placebo. Clin Pharmacol Ther. 53:1993;577-584.
40. Hamburg M.D., Cohen R.P. Memory access pathway Role of adrenergic versus cholinergic neurons . Pharmacol Biochem Behav. 1:1973;295-300.
41. Haroutunian V., Kanof P., Davis K.L. Pharmacological alleviation of cholinergic lesion-induced memory deficits in rats. Life Sci. 37:1985;945-952.
42. Haroutunian V., Kanof P.D., Tsuboyama G., Davis K.L. Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res. 507:1990;261-266.
43. Haroutunian V., Kanof P.D., Tsuboyama G.K., Campbell G.A., Davis K.L. Animal models of Alzheimer's disease Behavior, pharmacology, transplants . Can J Neurol Sci. 13:1986;385-393.
44. Hoogendijk W.J.G., Feenstra M.G.P., Botterblom M.H.A., Gilhuis J., Sommer I.E.C., Kamphorst W., et al. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol. 45:1999;82-91.
45. Huygens P., Baratti C.M., Gardella J.L., Filinger E. Brain catecholamines modifications. The effects on memory facilitation induced by oxotremorine in mice. Psychopharmacology (Berl). 69:1980;291-294.
46. Ikegaya Y., Nakanishi K., Saito H., Abe K. Amygdala β-noradrenergic influence on hippocampal long-term potentiation in vivo. Neuroreport. 8:1997;3143-3146.
47. Ikegaya Y., Saito H., Abe K. The basomedial and basolateral amygdaloid nuclei contribute to the induction of long-term potentiation in the dentate gyrus in vivo. Eur J Neurosci. 8:1996;1833-1839.
48. Iversen L.L., Rossor M.N., Reynolds G.P., Hills R., Roth M., Mountjoy C.Q., et al. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett. 39:1983;95-100.
49. Izquierdo I., Medina J.H., Izquierdo L.A., Barros D.M., de Souza M.M., Melo e Souza T. Short- and long-term memory are differentially regulated by monoaminergic systems in the rat brain. Neuobiol Learn Mem. 69:1998;219-224.
50. Johnston M.V., McKinney M., Coyle J.T. Neocortical cholinergic innervation A description of extrinsic and intrinsic components in the rat . Exp Brain Res. 43:1981;159-172.
51. 3H]p-aminoclonidine binding in prefrontal cortex . Neurobiol Aging. 12:1991;131-136.
52. Kemali D., Del-Vecchio M., Maj M. Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry. 17:1982;711-717.
53. Kobilka B.K., Matsui H., Kobilka T.S., Yang-Feng T.L., Caron M.G., Lefkowitz R.J., et al. Cloning and sequencing, and expression of the gene coding for the human platelet alpha-2 adrenergic receptor. Science. 238:1987;650-656.
54. Kugler J., Krauskoff R., Seus R., Brecht H.M., Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. J Clin Pharmacol. 10:1980;715-805.
55. Lake C.R., Sternberg D.E., van Kammen D.P., Ballenger J.C., Ziegler M.G., Post R.M., et al. Schizophrenia Elevated cerebrospinal fluid norepinephrine . Science. 207:1980;331-333.
56. Lawlor B.A., Bierer L.M., Ryan T.M., Schmeidler J., Knott P.J., Williams L.L., et al. Plasma 3-methoxy-4-hudroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biol Psychiatry. 38:1995;185-188.
57. Lo Conte G., Bartolini L., Casamenti F., Marconcini Pepeu I., Pepeu G. Lesions of cholinergic forebrain nuclei Changes in avoidance behavior and scopolamine actions . Pharmacol Biochem Behav. 17:1982;933-937.
58. Lomasney J.W., Lorenz W., Allen L.F., King K., Regan J.W., Yang-Feng T.L., et al. Expansion of the α-2 Adrenergic family Cloning and characterization of human α-2 adrenergic subtype, the gene for which is located on chromosome 2 . Proc Natl Acad Sci U S A. 87:1990;5094-5098.
59. Mair R.G., McEntee W.J. Cognitive enhancement in Korsakoff's psychosis by clonidine A comparison with L-dopa and ephedrine . Psychopharmacology. 88:1986;374-380.
60. Mann D.M., Lincoln J., Yates P.O., Stamp J.E., Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry. 136:1980;533-541.
61. Mann D.M., Yates P.O., Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry. 45:1982;113-119.
62. Mason S.T., Fibiger H.C. Noradrenaline and spatial memory. Brain Res. 156:1978;382-386.
63. Mason S.T., Fibiger H.C. Possible behavioural function for noradrenaline - acetylcholine interaction in brain. Nature. 277:1979;396.
64. Mason S.T., Iversen S.D. Theories of dorsal bundle extinction effects. Brain Res Rev. 1:1979;107-137.
65. Mason S.T., Iversen S.D. Effects of selective forebrain noradrenaline loss on behavioral inhibition in the rat. J Comp Physiol Psychol. 91:1977;165-173.
66. 99mTc-Exametazime in anterior cingulate cortex in Korsakoff's psychosis. Pschol Med. 24:1994;53-61.
67. Mohs R.C., Davis B.M., Johns C.A., Greenwald B.S., Mathe A.A., Horvath T.B., Davis K.L. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry. 142:1985;28-33.
68. Murray C.L., Fibiger H.C. Learning and memory deficits after lesions of the nucleus basalis magnocellularis Reversal by physostigmine . Neuroscience. 14:1985;1025-1032.
69. Murray C.L., Fibiger H.C. Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis. Behav Neurosci. 100:1986;23-32.
70. Nakamura S., Sakaguchi T. Development and plasticity of the locus coeruleus A review of recent physiological and pharmacological experimentation . Prog Neurobiol. 34:1990;505-526.
71. Nicholas A.P., Pieribone V., Hokfelt T. Distribution of mRNA's for a-2 adrenergic receptor subtypes in rat brain An in situ hybridization study . J Comp Neurol. 328:1993;575-594.
72. Palmer A.M., Sims N.R., Bowen D.M., Neary D., Palo J., Wikstrom J., et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry. 47:1984;481-484.
73. Palmer A.M., Francis P.T., Bowen D.M., Benton J.S., Neary D., Mann D.M.A., et al. Catecholaminergic neurons assessed ante-mortem in Alzheimer's disease. Brain Res. 414:1987;365-375.
74. Perry E.K., Blessed G., Tomlinson B.E., Perry R.H., Crow T.J., Cross A.J., et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging. 2:1981;251-256.
75. Peskind E.R., Elrod R., Dobie D.J., Pascualy M., Petrie E., Jensen C., et al. Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging. Neuropsychopharmacology. 19:1998;465-471.
76. Peskind E.R., Wingerson D., Murray S., Pascualy M., Dobie D.J., Le Corre P., et al. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry. 52:1995;774-782.
77. Peskind E.R., Wingerson D., Pascualy M., Thal L., Veith R.C., Dorsa D.M., et al. Oral physostigmine in Alzheimer's disease Effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma . Biol Psychiatry. 38:1995;532-538.
78. Powchik P., Davidson M., Haroutunian V., Gabriel S.M., Purohit D.P., Perl D.P., et al. Postmortem studies in schizophrenia. Schizophr Bull. 24:1998;325-341.
79. Raskind M.A., Peskind E.R., Halter J.B., Jimerson D.C. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry. 4:1984;343-346.
80. Regan J.W., Kobilka T.S., Yang Feng T.L., Caron M.G., Lefkowitz R.J., Kobilka B.K. Cloning and expression of a human kidney cDNA for an α-2 adrenergic receptor subtype. Proc Natl Acad Sci U S A. 85:1988;6301-6305.
81. Reis D.J., Granata A.R., Joh T.H., Ross C.A., Ruggiero D.A., Park D.H. Brain stem catecholamine mechanisms in tonic and reflex control of blood pressure. Hypertension. 6:(suppl 11):1984;7-15.
82. Ridley R.M., Murray T.K., Johnson J.A., Baker H.F. Learning impairment following lesion of the basal nucleus of Meynert in the marmoset Modification by cholinergic drugs . Brain Res. 376:1986;108-116.
83. Roberts R.B., Flexner J.B., Flexner L.B. Some evidence for the involvement of adrenergic sites in the memory trace. Proc Natl Acad Sci U S A. 66:1970;310-313.
84. Rogers S., Doody R., Mohs R. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alheimer's disease Results of a 30 week phase III trial . Neurology. 46:1996;suppl. A217.
85. Rossor M.N., Iversen L.L., Reynolds G.P., Mountjoy C.Q., Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J Clin Res Ed. 288:1984;961-964.
86. Rossor M.N. Neurotransmitters and CNS disease. Dementia. Lancet. 2:1982;1200-1204.
87. Scheinin M., Lomasney J.W., Hayden-Hixson D.M., Schambra U.B., Caron M.G., Lefkowitz R.J., et al. Distribution of α-2 adrenergic receptor subtype gene expression in rat brain. Mol Brain Res. 21:1994;133-149.
88. Schneider J.S., Sun Z.Q., Roeltgen D.P. Effects of dihydrexidine, a full dopamine receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 663:1994;140-144.
89. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J Neurochem. 47:1986;1295-1301.
90. Stein L., Belluzzi J.D., Wise C.D. Memory enhancement by central administration of norepinephrine. Brain Res. 84:1975;329-335.
91. Tohgi H., Ueno M., Abe T., Takahashi S., Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J Neural Transm Park Dis Dement Sect. 4:1992;69-77.
92. Tomlinson B.E., Irving D., Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci. 49:1981;419-428.
93. Uhlen S., Muceniece R., Rangel N., Tiger G., Wikberg J. Comparison of the binding activities of some drugs on α-2A, α-2B, α-2C adrenoreceptors in noradrenergic imidazoline sites in the guinea pig. Pharmacol Toxicol. 76:1995;353-364.
94. van Kammen D.P., Peters J., van Kammen W.B., Nugent A., Goetz K.L., Yao J., et al. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry. 26:1989;176-188.
95. van Kammen D.P., Peters J., Yao J., van Kammen W.B., Neylan T., Shaw D., et al. Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry. 47:1990;161-168.
96. van Kammen D.P., Peters J.L., van Kammen W.B., Rosen J., Yao J.K., McAdam D., Linnoila M. Clonidine treatment of schizophrenia Can we predict treatment response? Psychiatry Res. 27:1989;297-311.
97. van Stegeren A.H., Everaerd W., Cahill L., McGaugh J.L., Gooren L.J. Memory for emotional events Differential effects of centrally versus peripherally acting beta-blocking agents . Psychopharmacology (Berl). 138:1998;305-310.
98. Waterhouse B.D., Moises H.C., Woodward D.J. Alpha-receptor-mediated facilitation of somatosensory cortical neuronal responses to excitatory synaptic inputs and iontophoretically applied acetylcholine. Neuropharmacology. 20:1981;907-920.
99. Zigmond MJ, Acheson AL, Chiodi LA (1981): Abstr Soc Neurosci 7.